首页> 外文期刊>Journal of gastroenterology and hepatology >Radiotherapy for patients with unresectable advanced hepatoeellular carcinoma with invasion to-intrahepatic large vessels: Efficacy and outcomes
【24h】

Radiotherapy for patients with unresectable advanced hepatoeellular carcinoma with invasion to-intrahepatic large vessels: Efficacy and outcomes

机译:不能切除的晚期肝细胞癌合并向肝内大血管侵犯的放射治疗:疗效和结果

获取原文
获取原文并翻译 | 示例
       

摘要

Background and Aim: To examine the efficacy and outcomes of radiotherapy (RT) in patients who have hepatocellular carcinoma with invasion to intrahepatic large vessels (IHLVs).Methods: Sixty-seven patients who had advanced hepatoeellular carcinoma with invasion to IHLVs received three-dimensional conformal RT. IHLV invasion was associated with portal venous tumor thrombosis in 40 patients, tumor thrombosis involving the hepatic vein in 17, and both findings in 10. A daily radiation dose of 1.8-2 Gy was administered using 6 or 10 MV X-rays to deliver a total dose of 30-56 Gy. Results: The overall objective response rate (complete response plus partial response) was 45% (n = 30). The median survival time was 13.7 months in the responder group and 5.9 months in the nonresponder group. An objective response was observed in 28 (56%) of 50 patients with Child-Pugh (C-P) class A and in 2 (12%) of 17 patients with C-P class B. Hepatic function of C-P class A was an independent factor for both RT responder and overall survival on Cox regression analysis (hazard ratio = 9.5, 95% confidence interval = 1.97-46.2, P = 0.005; and hazard ratio = 0.39, 95% confidence interval = 0.2-0.77, P = 0.007, respectively). Conclusion: RT is an effective treatment option without serious adverse events. RT should be considered for the patients with better hepatic function who have invasion to IHLVs.
机译:背景与目的:研究放疗(RT)对肝细胞内大血管(IHLVs)侵袭的肝细胞癌患者的疗效和方法。方法:67例对IHLVs侵袭性晚期肝细胞癌的患者接受三维治疗适形RT。 IHLV入侵与40例患者的门静脉肿瘤血栓形成相关,其中17例涉及肝静脉的肿瘤血栓形成,二者均与10例结果相关。每天使用6或10 MV X线照射给予1.8-2 Gy的放射剂量总剂量为30-56 Gy。结果:总体客观缓解率(完全缓解加部分缓解)为45%(n = 30)。响应者组中位生存时间为13.7个月,无响应者中位生存时间为5.9个月。 50例Child-Pugh(CP)A级患者中有28名(56%)客观反应,17例CP B级患者中有2例(12%)观察到。CPA级肝功能是两者的独立因素RT响应者和Cox回归分析的总生存率(危险比= 9.5,95%置信区间= 1.97-46.2,P = 0.005;危险比= 0.39,95%置信区间= 0.2-0.77,P = 0.007)。结论:RT是一种有效的治疗选择,无严重不良事件。对于肝功能好,侵袭性IHLV的患者,应考虑放疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号